Unit 3: Bioenergetics

Unit 3: Bioenergetics

Introduction to Bioenergetics

Bioenergetics is the quantitative study of energy relationships and energy conversions in living cells. It encompasses the principles of thermodynamics as applied to biological systems and focuses on how cells harvest, store, and utilize energy to perform work. In pharmaceutical biochemistry, understanding bioenergetics is crucial for comprehending drug effects on energy metabolism, mitochondrial toxicity, and the development of therapeutics targeting metabolic disorders.

Key Concepts:

---

1. Principles of Bioenergetics

1.1 Thermodynamic Foundations

Biological systems obey the laws of thermodynamics:

• First law: Energy cannot be created or destroyed, only transformed. Cells convert chemical energy from nutrients into work and heat.
• Second law: Entropy (disorder) increases in spontaneous processes. Cells maintain order by exporting entropy to surroundings.

Gibbs Free Energy Equation: ΔG = ΔH – TΔS

Where:

• ΔG = change in free energy
• ΔH = change in enthalpy (heat content)
• T = absolute temperature (Kelvin)
• ΔS = change in entropy

1.2 Standard Free Energy Change (ΔG°′)

• ΔG°′ is the free energy change under standard conditions (1 M, 25°C, pH 7.0).
• Actual ΔG depends on concentrations of reactants and products: ΔG = ΔG°′ + RT ln([products]/[reactants])
• Reactions with large negative ΔG°′ are essentially irreversible under physiological conditions.

1.3 ATP: The Energy Currency of the Cell

ATP (adenosine triphosphate) is the primary energy carrier in cells. Hydrolysis of ATP to ADP and Pi releases energy that drives endergonic processes.

Phosphate Transfer Potential: A measure of the tendency of a compound to donate a phosphoryl group.

Why ATP is an ideal energy currency:

• Intermediate phosphate transfer potential (can donate to lower-energy acceptors and be formed from higher-energy donors)
• Hydrolytically stable (does not spontaneously decompose)
• Small and water-soluble
• Can be rapidly regenerated

1.4 Other High-Energy Compounds

• GTP: Used in protein synthesis, signal transduction, and TCA cycle (succinyl-CoA synthetase).
• UTP: Used in glycogen synthesis (UDP-glucose formation).
• CTP: Used in phospholipid synthesis.
• Phosphocreatine: Rapid reserve for ATP regeneration in muscle and brain.

1.5 Electron Carriers: NADH, NADPH, FADH₂

---

2. Electron Transport Chain (ETC)

2.1 Overview

The electron transport chain (ETC), also called the respiratory chain, is a series of protein complexes embedded in the inner mitochondrial membrane. It accepts electrons from NADH and FADH₂ (produced in glycolysis, TCA, fatty acid oxidation) and transfers them to molecular oxygen, forming water. The energy released during electron transfer is used to pump protons across the inner membrane, creating an electrochemical gradient that drives ATP synthesis.

2.2 Location and Components

Mitochondrial Structure:

• Outer membrane: permeable to small molecules
• Inner membrane: impermeable; contains ETC complexes and ATP synthase
• Matrix: site of TCA cycle, fatty acid oxidation
• Intermembrane space

Complexes of the ETC:

Mobile Electron Carriers:

• Ubiquinone (Coenzyme Q, Q): Lipid-soluble, moves within the membrane, shuttles electrons from Complexes I and II to III.
• Cytochrome c: Water-soluble protein in intermembrane space, shuttles electrons from Complex III to IV.

2.3 Electron Flow Pathway

NADH → Complex I → Q → Complex III → Cyt c → Complex IV → O₂
            ↓
FADH₂ (via Complex II) → Q
(Also electrons from fatty acyl-CoA via ETF:ubiquinone oxidoreductase feed into Q)

2.4 The Q Cycle (Complex III Mechanism)

Complex III transfers electrons from ubiquinol (QH₂) to cytochrome c via a two-step cycle that increases proton pumping efficiency.

1. QH₂ binds to Q₀ site; one electron goes to Rieske Fe-S → cytochrome c₁ → cytochrome c; the other to heme bL → heme bH → Q at Qᵢ site, forming semiquinone.
2. Second QH₂ repeats, reducing semiquinone to QH₂ at Qᵢ site (consumes 2H⁺ from matrix). Net: 2 QH₂ oxidized, 1 QH₂ formed, 4 H⁺ pumped (2 from Q₀ site to intermembrane space, 2 from matrix used at Qᵢ site).

2.5 Complex IV: Cytochrome c Oxidase

• Transfers electrons from cytochrome c to O₂, reducing it to H₂O.
• Contains copper centers (CuA, CuB) and heme a, a₃.
• Reaction: 4 cytochrome c (Fe²⁺) + 8 H⁺(matrix) + O₂ → 4 cytochrome c (Fe³⁺) + 2 H₂O + 4 H⁺(pumped)
• Highly efficient; almost all energy conserved.

2.6 Proton Motive Force (PMF)

Electron transport creates:

• Chemical gradient (ΔpH): higher [H⁺] in intermembrane space (acidic)
• Electrical gradient (ΔΨ): positive outside, negative inside

The proton motive force (PMF) = ΔΨ + (2.303 RT/F) ΔpH ≈ 200 mV under physiological conditions.

---

3. Oxidative Phosphorylation

3.1 Definition

Oxidative phosphorylation is the process by which ATP is synthesized using energy derived from the electron transport chain. It couples the exergonic flow of electrons to O₂ with the endergonic phosphorylation of ADP.

3.2 Chemiosmotic Theory (Peter Mitchell, 1961)

• Electron transport pumps protons out of the matrix.
• The resulting proton gradient stores energy.
• Protons flow back into the matrix through ATP synthase, driving ATP synthesis.
• This theory earned Mitchell the Nobel Prize in 1978.

3.3 ATP Synthase (Complex V)

Structure:

• F₁ subunit: Spherical head in matrix; contains catalytic sites (α₃β₃γδε). γ subunit rotates.
• F₀ subunit: Proton channel embedded in inner membrane (ab₂c₁₀–₁₄). Protons flow through F₀, causing rotation of c-ring, which drives γ subunit rotation in F₁.
• Rotation causes conformational changes in β subunits (open, loose, tight) that synthesize and release ATP.

Mechanism:

• Binding change mechanism (Paul Boyer, John Walker): Three β subunits cycle through three conformations:
  • O (open): Releases ATP
  • L (loose): Binds ADP + Pi
  • T (tight): Catalyzes ATP formation
• Each full rotation (360°) produces 3 ATP.

Proton/ATP stoichiometry: ~4 H⁺ per ATP (including transport of Pi and ADP/ATP exchange via antiporters). Older estimates were 3 H⁺/ATP.

3.4 ATP Yield from Complete Glucose Oxidation

3.5 Regulation of Oxidative Phosphorylation

• Respiratory control: ATP demand regulates electron transport. High ADP (low ATP) stimulates respiration; high ATP inhibits.
• Acceptor control ratio: Ratio of respiration rate with ADP present vs. without. Indicates coupling.
• Allosteric regulation: ATP inhibits, ADP activates isocitrate dehydrogenase and α-ketoglutarate dehydrogenase (TCA cycle), indirectly controlling NADH supply.
• Calcium: Activates several dehydrogenases (pyruvate, isocitrate, α-KG) and ATP synthase.

---

4. Disorders of Electron Transport Chain and Oxidative Phosphorylation

4.1 Inhibitors of ETC and Oxidative Phosphorylation

4.2 Uncouplers

Uncouplers dissociate electron transport from ATP synthesis by dissipating the proton gradient. Electrons continue to flow, but energy is released as heat.

Clinical consequence: Uncoupling leads to increased O₂ consumption, heat production, and potential cell damage due to ATP depletion.

4.3 Mitochondrial Diseases

Mitochondrial diseases result from mutations in mitochondrial DNA (mtDNA) or nuclear genes encoding ETC components. Tissues with high energy demand (CNS, muscle, heart, endocrine) are most affected.

4.4 Drug-Induced Mitochondrial Toxicity

Many drugs impair mitochondrial function, leading to adverse effects.

4.5 Ischemia-Reperfusion Injury

• During ischemia, electron transport halts due to lack of O₂, leading to ATP depletion, ion imbalances, and Ca²⁺ overload.
• Upon reperfusion, rapid electron flow combined with damaged complexes causes massive ROS production (see below), leading to cell death.

---

5. Reactive Oxygen Species (ROS)

5.1 Definition

Reactive oxygen species (ROS) are chemically reactive molecules containing oxygen. They are produced as byproducts of normal metabolism, especially during electron transport, and also by dedicated enzymes.

5.2 Major ROS

5.3 Sites of ROS Production in ETC

• Complex I: Electron leakage from FMN or Fe-S clusters, especially when high NADH/NAD⁺ ratio or damage.
• Complex III: Ubisemiquinone intermediate at Q₀ site can donate electrons to O₂, forming O₂•⁻ (released into intermembrane space and matrix).
• Other mitochondrial sources: Glycerol-3-phosphate dehydrogenase, dihydroorotate dehydrogenase, pyruvate and α-ketoglutarate dehydrogenases (minor).

5.4 Physiological Roles of ROS

• Signal transduction: H₂O₂ modulates activity of kinases, phosphatases, transcription factors (e.g., NF-κB, HIF-1α).
• Immune defense: Phagocytes produce ROS via NADPH oxidase to kill pathogens.
• Cellular differentiation and proliferation: ROS influence cell cycle.
• Hormone synthesis: Thyroid peroxidase uses H₂O₂ for iodination of thyroglobulin.

5.5 Pathological Effects of ROS (Oxidative Stress)

When ROS production exceeds antioxidant capacity, oxidative stress damages cellular components:

Diseases associated with oxidative stress:

• Neurodegenerative (Alzheimer's, Parkinson's, ALS)
• Cardiovascular (atherosclerosis, heart failure)
• Ischemia-reperfusion injury
• Inflammatory diseases
• Diabetes complications
• Aging
• Cancer

---

6. Antioxidant Defense Systems

Cells have multiple antioxidant mechanisms to neutralize ROS.

6.1 Enzymatic Antioxidants

6.2 Non-Enzymatic Antioxidants

6.3 The Glutathione System

Glutathione (γ-glutamylcysteinylglycine) is the most abundant intracellular thiol. Its reduced form (GSH) maintains redox balance.

Cycle:

• GSH + ROS → GSSG (via GPx or direct reaction)
• GSSG + NADPH → 2 GSH (via glutathione reductase)
• NADPH is supplied mainly by pentose phosphate pathway (G6PD)

Importance in drug metabolism: Glutathione S-transferases (GST) conjugate GSH to electrophilic xenobiotics (detoxification). Depletion of GSH (e.g., by acetaminophen overdose) leads to oxidative damage and hepatotoxicity.

6.4 Antioxidant Therapeutic Strategies

• N-Acetylcysteine (NAC) : Replenishes GSH; used in acetaminophen overdose, chronic obstructive pulmonary disease, etc.
• Edaravone: Free radical scavenger; used in ALS, stroke.
• Vitamin E: Used in some neurodegenerative conditions; controversial efficacy.
• Coenzyme Q10: Supplement in mitochondrial diseases, statin-induced myopathy.
• Mitochondria-targeted antioxidants (e.g., MitoQ, MitoTEMPO) – experimental.

---

7. Summary Tables

Table 1: ETC Complexes and Inhibitors

Table 2: ROS and Antioxidant Defenses

Table 3: Clinical Conditions Associated with ETC/ROS

---

References

1. Lippincott Williams & Wilkins. (2020). Lippincott's illustrated reviews: Biochemistry. (Chapters on Bioenergetics, ETC, and Oxidative Phosphorylation)

2. Berg, J. M., Tymoczko, J. L., & Gatto, G. J. (2019). Stryer's biochemistry (8th ed.). W. H. Freeman and Company. (Chapters on Oxidative Phosphorylation and Reactive Oxygen Species)

3. Nelson, D. L., & Cox, M. M. (2017). Lehninger principles of biochemistry (7th ed.). W. H. Freeman and Company. (Chapters on Electron Transport and Oxidative Phosphorylation)

4. Rodwell, V. W., Bender, D. A., Botham, K. M., Kennelly, P. J., & Weil, P. A. (2017). Harper's illustrated biochemistry (31st ed.). McGraw-Hill Education. (Chapters on Biological Oxidations and Antioxidants)

5. Devlin, T. M. (2016). Textbook of biochemistry with clinical correlations (8th ed.). Wiley-Liss. (Chapters on Bioenergetics and Mitochondrial Function)

6. Halliwell, B., & Gutteridge, J. M. C. (2015). Free radicals in biology and medicine (5th ed.). Oxford University Press. (Comprehensive coverage of ROS and antioxidants)

7. DiMauro, S., & Schon, E. A. (2003). Mitochondrial respiratory-chain diseases. New England Journal of Medicine, 348(26), 2656–2668.

8. Wallace, D. C. (2005). A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annual Review of Genetics, 39, 359–407.

9. Dykens, J. A., & Will, Y. (2007). The significance of mitochondrial toxicity testing in drug development. Drug Discovery Today, 12(17-18), 777–785.

---

Recommended Textbooks for Further Reading:

• Lippincott Williams & Wilkins. (2020). Lippincott's illustrated reviews: Biochemistry. (Excellent for visual summaries and clinical notes)
• Nelson, D. L., & Cox, M. M. (2017). Lehninger principles of biochemistry (7th ed.). (Detailed mechanistic explanations)
• Halliwell, B., & Gutteridge, J. M. C. (2015). Free radicals in biology and medicine (5th ed.). (Definitive text on oxidative stress)